Pain News and Research

Latest Pain News and Research

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

XenoPort announced today that data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the Associated Professional Sleep Society meeting in San Antonio, Texas.

7 Jun 2010

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine continues to produce promising efficacy results in patients with previously untreated, inoperable, locally advanced or metastatic pancreatic cancer.

7 Jun 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting.

7 Jun 2010

Positive results from new analyses of denosumab Phase 3 trials

Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.

5 Jun 2010

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Most Canadians would describe sexual desire as feelings of longing, craving, satisfying a sensuous appetite, or even the need for sensual indulgence. Today, the Society of Obstetricians and Gynaecologists of Canada wants to explain that desire is more than just a "feeling". The SOGC wants Canadian women to better understand the physical and psychosocial causes that may predispose to, precipitate or maintain a loss of desire.

5 Jun 2010

Burden of substance abuse casts tragic shadow on the lives of many young people: Report

On an average day, 508,000 adolescents aged 12-17 in the United States drink alcohol; 641,000 use illicit drugs; and more than 1 million smoke cigarettes, according to a national survey sponsored by the Substance Abuse and Mental Health Services Administration.

5 Jun 2010

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment.

5 Jun 2010

US dental school graduates not adequately prepared to screen for sleep disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the majority of U.S. dental schools have not adequately prepared their graduates to screen for sleep disorders, which affect more than 70 million adults in the U.S.

5 Jun 2010

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Faculty at the Johns Hopkins Berman Institute of Bioethics have published a study that shows, among adults with sickle cell disease, that unsatisfactory interactions with health-care providers in the past affect their trust in the medical profession more broadly.

5 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

Water is essential but electrolyte drinks are needed when exercising in heat

Water is essential when exercising in the heat but it might not be enough to keep you healthy in Houston summers.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Hip strengthening regimen proves effective at reducing PFP in female runners: Study

A twice weekly hip strengthening regimen performed for six weeks proved surprisingly effective at reducing -- and in some cases eliminating -- knee pain referred to as patellofemoral pain in female runners.

5 Jun 2010

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command.

5 Jun 2010

Pain News and Research

Latest Pain News and Research

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Positive results from new analyses of denosumab Phase 3 trials

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Burden of substance abuse casts tragic shadow on the lives of many young people: Report

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

US dental school graduates not adequately prepared to screen for sleep disorders

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Water is essential but electrolyte drinks are needed when exercising in heat

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Hip strengthening regimen proves effective at reducing PFP in female runners: Study

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Pain News and Research

Latest Pain News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in